Physician profile
Andre J Witkin
NPI 1285811216
$22,709.25
in general payments reported to CMS, 2019-2025
26 companies · $5,118 in 2025
The $5,118 reported for 2025 was more than what 87% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,227 · 2020: $25.45 · 2021: $2,136 · 2022: $203 · 2023: $5,060 · 2024: $2,940 · 2025: $5,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,145 · Food and Beverage: $3,268 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,512 · Travel and Lodging: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,145.00 |
| Food and Beverage | $3,268.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,512.00 |
| Travel and Lodging | $192.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,339.45 | 2021-2025 | Susvimo, Vabysmo |
| Novartis Pharmaceuticals Corporation | $2,743.33 | 2019 | |
| Genentech, INC. | $2,634.66 | 2023-2025 | Susvimo, Vabysmo |
| Cortigent INC | $2,500.00 | 2019 | |
| Alcon Vision LLC | $1,834.59 | 2019-2025 | Constellation, Ngenuity |
| Abbvie INC. | $1,794.07 | 2022-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $1,668.92 | 2024 | Syfovre |
| Eyepoint US, INC. | $1,620.00 | 2021 | |
| Allergan, INC. | $1,371.84 | 2019 | |
| Bausch & Lomb Americas INC. | $1,319.71 | 2023-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Regeneron Pharmaceuticals, INC. | $508.45 | 2019-2024 | Eylea Hd |
| Alimera Sciences, INC. | $283.39 | 2019-2023 | Iluvien |
| Neurotech Pharmaceuticals, INC. | $233.78 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $231.38 | 2019-2024 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $187.81 | 2024-2025 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $102.96 | 2024 | Cimerli |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $57.37 | 2023 | Cequa |
| Coherus Oncology, INC. | $35.16 | 2024 | |
| Oyster Point Pharma, INC. | $26.89 | 2024 | Tyrvaya |
| Amgen INC. | $26.09 | 2024 | Tepezza |
| Dompe US, INC. | $26.08 | 2024 | Oxervate |
| Harrow Eye, LLC | $23.99 | 2024 | |
| Horizon Therapeutics Plc | $23.95 | 2023 | Tepezza |
| Sight Sciences, INC. | $23.74 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $21.88 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Witkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.